A study by New York University researchers, published this week in the journal Proceedings of the National Academy of Sciences, explains why cancers not only stop responding to kinase inhibitors but come back stronger, a finding that could inform which drugs oncologists use as a first-line treatment.
Jonathan M. Gerber was named chief clinical officer of NYU Langone Health’s Perlmutter Cancer Center.
